749697
Last Update Posted: 2008-09-09
Recruiting status is unknown
All Genders accepted | 18 Years + |
10 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
The main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.
Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid cancer to correlate the administered activity to absorbed dose. Patients will receive the standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for the protocol purpose.
Eligibility
Relevant conditions:
Thyroid Carcinoma
Metastatic Sites Lung Bone Nodal
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Dr Kate Newbold
kate.newbold@rmh.nhs.uk
020 86613638
Dr Prasad Dandekar
prasad.dandekar@rmh.nhs.uk
020 8661 3454
Data sourced from ClinicalTrials.gov